![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » SANGAMO BIOSCIENCES FILES IND APPLICATION FOR ZFP THERAPEUTIC TO TREAT DIABETIC NEUROPATHY
SANGAMO BIOSCIENCES FILES IND APPLICATION FOR ZFP THERAPEUTIC TO TREAT DIABETIC NEUROPATHY
Sangamo BioSciences has submitted an investigational new drug application to the FDA for SB-509, a novel therapeutic designed to protect and stimulate the regeneration of peripheral nerve function in diabetics suffering from peripheral neuropathy.
SB-509 is an injectable formulation of plasmid DNA that encodes a zinc finger DNA-binding protein transcription factor, designed to upregulate the vascular endothelial growth factor A (VEGF-A) gene. VEGF-A has been demonstrated to have direct neuroproliferative, neuroregenerative and neuroprotective properties. In preclinical animal efficacy studies, SB-509 has proven effective in protecting motor and sensory nerve function in a diabetic model and in stimulating nerve regeneration.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
11Jul
-
18Jul
-
21Oct